Dr. Ding received his PhD in Statistics in 1999 from the University of Alberta, and subsequently did postdoctoral training in the Department of Biostatistics at the University of Rochester. He joined the Canadian Cancer Trials Group and Department of Community Health & Epidemiology at Queen's in 2001. As a Senior Biostatistician at Canadian Cancer Trials Group, his primary responsibilities are the design and analysis of the cancer clinical trials conducted by the Group. Dr. Ding is also interested in sequential analysis, statistical quality control procedures, and, statistical computing.
Areas of expertise:
Statistical methods in design and analysis of clinical trials; Discovery and validation of prognostic and predictive Biomarkers, High-throughput data analysis: health economic analysis along the cancer clinical trials; survival analysis; sequential analysis; and statistical computing.
Research interests: Lung and Genito-urinary statistics, symtoms control and brain cancer disease sities, and the correlative sciences committee in Canadian Cancer Trials Group (CCTG). Keyue also has a long-standing interest in innovative statistical methods in design and analysis of clinical trials, in validation and discovery of prognostic and predictive Biomarkers, in high-throughput data analysis, health economic analysis along the cancer clinical trials; survival analysis; sequential analysis; and statistical computing.
Lung cancer trials: BR31, BR34 and BR36.
Genito-urinary Trials: BL13; PR19, PR20 and PR21.
Symptoms control Trials: SC24, and SC26.
Brain Cancer Trial: CE7.
For a full list of publications please visit PubMed